Activation of local aldosterone system within podocytes is involved in apoptosis under diabetic conditions

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 5, 2009, Pages

  Lee, Sun Ha ^a   Yoo, Tae Hyun ^a   Nam, Bo Young ^a   Kim, Dong Ki ^a   Li, Jin Ji ^a,b   Jung, Dong Sub ^a   Kwak, Seung Jae ^a   Ryu, Dong Ryeol ^c   Han, Seung Hyeok ^a   Lee, Jung Eun ^a   Moon, Sung Jin ^a   Han, Dae Suk ^a   Kang, Shin Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

^b YANBIAN UNIVERSITY MEDICAL COLLEGE   (China)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Aldosterone; Apoptosis; Diabetic nephropathy; High glucose; Podocytes

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE; CASPASE 3; GLUCOSE; MANNITOL; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PROTEIN BAX; PROTEIN BCL 2; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STREPTOZOCIN DIABETES; TIME;

EID: 70350710165     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00101.2009     Document Type: Article

References (43)

1. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 5: 1165-1172, 1994. (Pubitemid 24977097)
2. Burniston JG, Saini A, Tan LB, Goldspink DF. Aldosterone induces myocyte apoptosis in the heart, and skeletal muscles of rats in vivo. J Mol Cell Cardiol 39: 395-399, 2005. (Pubitemid 40995029)
3. +-antiport. Hypertension 25: 117-123, 1995.
4. European Dialysis, and Transplant Association. Report on management of renal failure in Europe, XXVI, 1995. Nephrol Dial Transplant 11, Suppl 7: 1-32, 1996.
5. Fejes-Toth G, Naray-Fejes-Toth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? Endocrinology 148: 1502-1510, 2007. (Pubitemid 46457129)
6. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66: 1493-1502, 2004. (Pubitemid 39298382)
7. Guo C, Martinez-Vasquez D, Mendez GP, Toniolo MF, Yao TM, Oestreicher EM, Kikuchi T, Lapointe N, Pojoga L, Williams GH, Ricchiuti V, Adler GK. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1, and 2 diabetes mellitus. Endocrinology 147: 5363-5373, 2006.
8. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR. Spironolactone ameliorates renal injury, and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111-120, 2006. (Pubitemid 44000127)
9. Han SY, Kim CH, Kim HS, Jee YH, Song HK, Lee MH, Han KH, Kim HK, Kang YS, Han JY, Kim YS, Cha DR. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 17: 1362-1372, 2006.
10. Haseroth K, Gerdes D, Berger S, Feuring M, Günther A, Herbst C, Christ M, Wehling M. Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor-knockout mice. Biochem Biophys Res Commun 266: 257-261, 1999. (Pubitemid 30028801)
11. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316-24320, 1994. (Pubitemid 24978846)
12. Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Yamamuro M, Harada M, Saito Y, Nakao K, Kurihara H, Yasue H, Ogawa H. Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 107: 807-810, 2003.
13. Karmazyn M, Liu Q, Gan XT, Brix BJ, Fliegel L. Aldosterone increases NHE1 expression, induces NHE1-dependent hypertrophy in neonatal rat ventricular myocytes. Hypertension 42: 1171-1176, 2003. (Pubitemid 37549073)
14. Lai L, Chen J, Hao CM, Lin S, Gu Y. Aldosterone promotes fibronectin production through a Smad2-dependent TGF-β1 pathway in mesangial cells. Biochem Biophys Res Commun 348: 70-75, 2006. (Pubitemid 44163483)
15. Lai LY, Gu Y, Chen J, Yu SQ, Ma J, Yang HC, Lin SY. Production of aldosterone by rat mesangial cell, and the accumulation of extracellular matrix induced by aldosterone. Natl Med J Chin 83: 1900-1905, 2004.
16. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400-2406, 2003. (Pubitemid 37413549)
17. Mano A, Tatsumi T, Shiraishi J, Keira N, Nomura T, Takeda M, Nishikawa S, Yamanaka S, Matoba S, Kobara M, Tanaka H, Shirayama T, Takamatsu T, Nozawa Y, Matsubara H. Aldosterone directly induces myocyte apoptosis through calcineurin-dependent pathways. Circulation 110: 317-323, 2004. (Pubitemid 38955501)
18. Mihailidou AS, Mardini M, Funder JW. Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 145: 773-780, 2003. (Pubitemid 38183820)
19. Mortensen RM, Williams GH. Aldosterone action. In: Endocrinology (4th ed.), edited by DeGroot LJ. Philadelphia, PA: Saunders, 2001, p. 1783-1790.
20. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R. Rearrangements of the cytoskeleton, and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258, 1997. (Pubitemid 27452369)
21. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats, and is reversed by aldosterone blocker. Hypertension 47: 1084-1093, 2006.
22. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 281: E1122-E1127, 2001.
23. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, Chrousos G. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 96: 309-316, 2005. (Pubitemid 41080512)
24. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003.
25. Sanden SK, Wiggins JE, Goyal M, Riggs LK, Wiggins RC. Evaluation of a thick, and thin section method for estimation of podocyte number, glomerular volume, and glomerular volume per podocyte in rat kidney with Wilms' tumor-1 protein used as a podocyte nuclear marker. J Am Soc Nephrol 14: 2484-2493, 2003.
26. Shankland SJ. The podocyte's response to injury: Role in proteinuria, and glomerulosclerosis. Kidney Int 69: 2131-2147, 2006. (Pubitemid 43882099)
27. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress, and Sgk1. Hypertension 49: 355-364, 2007. (Pubitemid 46143013)
28. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone, and corticosterone in the rat. Physiological regulation. J Biol Chem 273: 4883-4891, 1998. (Pubitemid 28108638)
29. Siragy HM, Xue C. Local renal aldosterone production induces inflammation, and matrix formation in kidneys of diabetic rats. Exp Physiol 93: 817-824, 2008. (Pubitemid 351904248)
30. Slight SH, Joseph J, Ganjam VK, Weber KT. Extra-adrenal mineralocorticoids, and cardiovascular tissue. J Mol Cell Cardiol 31: 1175-1184, 1999.
31. Taira M, Toba H, Murakami M, Iga I, Serizawa R, Murata S, Kobara M, Nakata T. Spironolactone exhibits direct renoprotective effects, and inhibits renal renin-angiotensin-aldosterone system in diabetic rats. Eur J Pharmacol 589: 264-271, 2008.
32. Takeda Y, Miyamori I, Yoneda T, Hatakeyama H, Inaba S, Furukawa K, Mabuchi H, Takeda R. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II, and adrenocorticotropin. J Clin Endocrinol Metab 81: 2797-2800, 1996. (Pubitemid 26323867)
33. Tryggvason K, Wartiovaara J. Molecular basis of glomerular permselectivity. Curr Opin Nephrol Hypertens 10: 543-549, 2001.
34. United States Renal Data System. 2005 Annual Data Report: Incidence & Prevalence. Am J Kidney Dis 47, Suppl 1: 65-80, 2006.
35. Wehling M, Armanini D, Strasser T, Weber PC. Effect of aldosterone on the sodium, and potassium concentrations in human mononuclear leukocytes. Am J Physiol Endocrinol Metab 252: E505-E508, 1987.
36. 2+ in vascular smooth muscle cells. Circ Res 76: 973-979, 1995.
37. Wehling M, Ulsenheimer A, Schneider M, Neylon C, Christ M. Rapid effects of aldosterone on free intracellular calcium in vascular smooth muscle, and endothelial cells: subcellular localization of calcium elevations by single cell imaging. Biochem Biophys Res Commun 204: 475-481, 1994.
38. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 10: 7-13, 2005. (Pubitemid 40895311)
39. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 34: 785-796, 2004. (Pubitemid 39657924)
40. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634, 2005. (Pubitemid 40770751)
41. Wu P, Liang X, Dai Y, Liu H, Zang Y, Guo Z, Zhang R, Lai W, Zhang Y, Liu Y. Aldosterone biosynthesis in extraadrenal tissues. Chin Med J 112: 414-418, 1999.
42. Kip1 expression in glucose-stimulated podocytes, and in diabetic glomeruli. Kidney Int 67: 944-952, 2005.
43. Xue C, Siragy HM. Local renal aldosterone system, and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46: 584-590, 2005. (Pubitemid 41379384)